Chaperone’s Scientific Advisory Board
Chaperone’s therapeutic development programs are making rapid advances guided by a Scientific Advisory Board comprised of leading figures in chaperone and cell stress protection biology, small molecule screening and drug development, animal models of neurodegenerative disease and clinical trials.
Dennis J. Thiele, Ph.D., Chair
Dr. Thiele is the George Barth Geller Distinguished Professor of Pharmacology and Cancer Biology, and Biochemistry, at the Duke University School of Medicine. Thiele’s innovative research on cellular stress protection and protein misfolding spans over 25 years. Dr. Thiele’s work has been recognized by his election as a Fellow of the American Association for the Advancement of Science (AAAS), as Chair of the Biological Sciences Division of AAAS and as a member of the American Academy of Microbiology. Dr. Thiele, a Founder of Chaperone Therapeutics, is a leading international figure in the pharmacological augmentation of cellular protein folding mechanisms.
Marie-Francoise Chesselet, M.D., Ph.D.
Dr. Chesselet is the Charles H. Markham Professor of Neurology and Distinguished Professor in the Department of Neurology and the Department of Neurobiology at the University of California-Los Angeles David Geffen School of Medicine. Dr. Chesselet, who received her M.D. and Ph.D. degrees in Paris, Chaired the Department of Neurobiology at UCLA from 2002 to 2013 and is currently Director of the Integrative Center for Neural Repair, which includes the Center for the Study of Parkinson’s Disease at UCLA, which she created in 1998. She has directed the NIH-funded UCLA UDALL Center for Parkinson’s Disease Research, the UCLA Center for Gene Environment in Parkinson’s Disease and the UCLA Advanced Center for Parkinson’s Disease Research. Dr. Chesselet is an expert in the development and analysis of animal models of Parkinson’s and Huntington’s Disease and other proteopathies. Her laboratory research focuses on the molecular mechanisms of disorders of the basal ganglia and new treatments for Parkinson’s and Huntington’s Diseases.
Francis Walker, M.D.
Dr. Walker is Professor of Neurology and Founding member and Director of the Movement Disorders Clinic at the Wake Forest University School of Medicine. Dr. Walker has been involved in clinical care and research in Huntington’s Disease for over 25 years, where he has made major contributions in disease etiology and therapeutics with seminal investigations of clinical marker identification, therapeutic efficacy evaluation and genetic linkage studies. Dr. Walker’ extensive expertise in Huntington’s Disease, Parkinson’s Disease and other neurodegenerative disorders has been recognized by his election as a Fellow of the American Academy of Neurology and the American Clinical Neurophysiology Society. Dr. Walker is a member of the Huntington’s and Parkinson’s Disease Study Groups, on the Medical Leadership Committee of the Huntington Disease Reach Foundation and serves on other neurodegenerative disease research and patient support advocacy groups.
John M. McCall, Ph.D.
Dr. McCall is an experienced medicinal chemist with a track record of discovering and developing drugs. He has held scientific and executive positions in major pharmaceutical companies including Pharmacia, Upjohn and Pfizer, where he served as Vice President for Research. Dr. McCall is the founder of PharMac LLC, which facilitates drug discovery and development. He serves in advisory roles for the NIH National Institute of Neurological Diseases and Stroke (NINDS Blueprint and NeuroNext Programs) and for a number of pharmaceutical companies and disease foundations.
Hilal Lashuel, Ph.D.
Dr. Lashuel is an Associate Professor of Neuroscience in the Brain Mind Institute and Director of the Laboratory of Chemical Biology of Neurodegeneration at the École Polytechnique Fédérale de Lausanne, Switzerland. Dr. Lashuel’s research program has led to 1) the identification and structural and biochemical characterization of novel intermediates on the amyloid formation pathway; 2) identification of novel therapeutic targets and; 3) the formulation of new hypotheses related to the mechanisms by which protein misfolding and aggregation contribute to neurodegeneration in neurological diseases including Alzheimer’s disease, Parkinson’s disease and Huntington’s disease. Dr. Lashuel received his Ph.D. from Texas A&M/Scripps Institute and carried out his postdoctoral training at the Center for Neurologic Diseases at Harvard Medical School.